Trial
NCT02145910
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Genentech, Inc.
Condition
Recurrent Melanoma
Intervention
Vemurafenib
Why stopped
Study was never opened to accrual. There is no clinical benefit to patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-02